help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Garvey, W. T.
Right arrow Articles by Marshall, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garvey, W. T.
Right arrow Articles by Marshall, S.

Endocrinology, Vol 124, 2063-2073, Copyright © 1989 by Endocrine Society


ARTICLES

Dexamethasone regulates the glucose transport system in primary cultured adipocytes: different mechanisms of insulin resistance after acute and chronic exposure

WT Garvey, TP Huecksteadt, R Monzon and S Marshall
Department of Medicine, Indiana University Medical Center, Indianapolis 46202.

We have studied the ability of dexamethasone to regulate the glucose transport system in primary cultured adipocytes and delineated the mechanisms of insulin resistance after both acute and chronic treatment. Acutely, 20 nM dexamethasone led to a 65% decrease in basal and a 31% decrement in maximally insulin-stimulated glucose transport (ED50 = 3-4 nM; t1/2 = 50 min). These effects were maximal by 90-120 min, and a plateau was maintained over an additional 1-1.5 h. Chronic dexamethasone exposure (24 h) led to a more profound decrease in basal (77%; ED50 = 0.4 nM) and maximally stimulated (55%; ED50 = 1.0 nM) rates of glucose transport and shifted the transport: insulin dose- response curve to the right by increasing the half-maximally effective insulin concentration from 0.2 to 0.4 ng/ml. Dexamethasone did not affect cell surface insulin binding over 24 h. Both the short and long term effects of dexamethasone were partially blocked by the combined presence of insulin during preincubation and were not modulated by glucose. We also assessed effects on the number and cellular distribution of glucose transporter proteins using the cytochalasin-B binding assay. After 2 h, dexamethasone (30 nM) decreased the number of glucose transporters in plasma membranes by 30% in basal cells and by 41% in maximally insulin-stimulated cells, while increasing the number of low density microsomal transporters by 22-23% (P = NS). Transporter number in a total cellular membrane fraction was unaltered by short term dexamethasone. Chronic dexamethasone exposure (24 h) decreased plasma membrane and low density microsomal transporters by 30-50% in both basal and insulin-stimulated cells and depleted transporters by 43% in a total cellular membrane fraction. In conclusion, 1) dexamethasone induces progressive insulin resistance by sequentially regulating multiple aspects of the insulin-responsive glucose transport system. At early times (2 h) dexamethasone impairs insulin's ability to translocate intracellular glucose transporters to the cell surface and with more chronic exposure (24 h), depletes the total number of cellular transporters. 2) Glucose modulates desensitization of the glucose transport system by insulin, but not by dexamethasone, and thus, there are both glucose-dependent and -independent mechanisms of insulin resistance. 3) Insulin can heterologously inhibit dexamethasone's effects on glucose transport at both early and late phases of desensitization. These studies highlight the complex hormonal regulation at the glucose transport system.


This article has been cited by other articles:


Home page
EndocrinologyHome page
M. Lowenberg, J. Tuynman, M. Scheffer, A. Verhaar, L. Vermeulen, S. van Deventer, D. Hommes, and M. Peppelenbosch
Kinome Analysis Reveals Nongenomic Glucocorticoid Receptor-Dependent Inhibition of Insulin Signaling
Endocrinology, July 1, 2006; 147(7): 3555 - 3562.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Lundgren, J. Buren, T. Ruge, T. Myrnas, and J. W. Eriksson
Glucocorticoids Down-Regulate Glucose Uptake Capacity and Insulin-Signaling Proteins in Omental But Not Subcutaneous Human Adipocytes
J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2989 - 2997.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
S. M. Willi, A. Kennedy, P. Wallace, E. Ganaway, N. L. Rogers, and W. T. Garvey
Troglitazone Antagonizes Metabolic Effects of Glucocorticoids in Humans: Effects on Glucose Tolerance, Insulin Sensitivity, Suppression of Free Fatty Acids, and Leptin
Diabetes, October 1, 2002; 51(10): 2895 - 2902.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
T. Hahn, S. Barth, R. Graf, M. Engelmann, D. Beslagic, J. M. H. M. Reul, F. Holsboer, G. Dohr, and G. Desoye
Placental Glucose Transporter Expression Is Regulated by Glucocorticoids
J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1445 - 1452.
[Abstract] [Full Text]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
T. Ishizuka, K. Kajita, A. Miura, M. Ishizawa, Y. Kanoh, S. Itaya, M. Kimura, N. Muto, T. Mune, H. Morita, et al.
DHEA improves glucose uptake via activations of protein kinase C and phosphatidylinositol 3-kinase
Am J Physiol Endocrinol Metab, January 1, 1999; 276(1): E196 - E204.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1989 by The Endocrine Society